2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. 2010

Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.

For the development of novel antitumor agents, 2,6-dithienyl-4-furyl pyridine derivatives were prepared and evaluated for their topoisomerase I and II inhibitory activity as well as cytotoxicity against several human cancer cell lines. Among the 21 prepared compounds, compound 24 exhibited strong topoisomerase I inhibitory activity. In addition, a docking study with topoisomerase I and compound 24 was performed.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013876 Thiophenes A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur. Thiophene

Related Publications

Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
July 2015, Bioorganic & medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
March 2012, European journal of medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
January 2010, Bioorganic & medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
May 2010, Bioorganic & medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
July 2015, Bioorganic & medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
March 2010, Bioorganic & medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
March 2004, Bioorganic & medicinal chemistry letters,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
September 2014, European journal of medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
August 2011, European journal of medicinal chemistry,
Arjun Basnet, and Pritam Thapa, and Radha Karki, and Hoyoung Choi, and Jae Hun Choi, and Minho Yun, and Byeong-Seon Jeong, and Yurngdong Jahng, and Younghwa Na, and Won-Jea Cho, and Youngjoo Kwon, and Chong-Soon Lee, and Eung-Seok Lee
April 2014, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!